Novavax and Gavi (Vaccine Alliance) announce an agreement for anti-covid immunization in poor countries

MADRID, 22 Feb. (EUROPA PRESS) –

The pharmaceutical company Novavax and Gavi, the Vaccine Alliance, announced this Thursday that they have reached an agreement regarding the 2021 Advance Purchase Agreement (APA) for Novavax’s Covid-19 vaccine prototype (NVX-CoV2373 ), thus ending the pending arbitration related to said APA.

“Novavax is pleased to have reached this agreement with Gavi, as it gives us the opportunity to continue working together towards our shared mission of ensuring equitable access to safe and effective vaccines,” said Novavax President and CEO John Jacobs. “We look forward to establishing a long-term partnership with Gavi to provide continued access to our protein-based mRNA-free vaccine,” he added.

For his part, Gavi’s interim CEO, David Marlow, “welcomed” the agreement, as it will allow the organization to focus on its “main programmatic objectives”, which include providing people with access to Covid vaccines. vulnerable people from low-income countries. “It is good for global immunization, for countries and for healthy manufacturing markets,” Marlow summarized.

Under the terms, the pharmaceutical company has made an initial payment of 75 million dollars (69.3 million euros) to Gavi and has agreed to make deferred payments of 80 million dollars (73.9 million euros) annually until December 31. December 2028, which mature in quarterly installments and total up to 400 million dollars (369.6 million euros).

Novavax’s annual cash obligation would be offset or reduced under an $80 million annual vaccine credit that can be used for qualified sales of any of the company’s Gavi-financed vaccines for supply to low-income countries and middle-low. Using the annual vaccine credit for qualified sales would reduce Novavax’s commitment.

In addition to the annual obligation, Novavax will provide an additional vaccine credit of up to $225 million (€207.9 million), should there be additional demand, which may be applied to purchases of doses of any of the vaccines in the laboratory in said countries throughout the five years of validity.

Post Views: 902